Anaptysbio (ANAB) Net Income towards Common Stockholders (QoQ) (2016 - 2026)
Powered by 
Analysis
Anaptysbio (ANAB) Net Income towards Common Stockholders (QoQ) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.80 Bn | 130.95 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.54 Bn | 77.55 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.07 Bn | 52.93 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.01 Bn | 44.01 Bn | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.40 Bn | 32.09 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn |
| 10 | Anaptysbio | 1.62 Bn | 1.34 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -200.69% |
| Dec 31, 2025 | 247.52% |
| Sep 30, 2025 | 139.12% |
| Jun 30, 2025 | 1.78% |
| Mar 31, 2025 | -558.49% |
| Dec 31, 2024 | 126.11% |
| Sep 30, 2024 | 29.59% |
| Jun 30, 2024 | -6.20% |
| Mar 31, 2024 | -459.41% |
| Dec 31, 2023 | 78.95% |
| Sep 30, 2023 | 6.37% |
| Jun 30, 2023 | 0.18% |
| Mar 31, 2023 | -80.33% |
| Dec 31, 2022 | 19.13% |
| Sep 30, 2022 | -2.54% |
| Jun 30, 2022 | 15.01% |
| Mar 31, 2022 | -1.02% |
| Dec 31, 2021 | -364.08% |
| Sep 30, 2021 | -1,461.54% |
| Jun 30, 2021 | 97.64% |